Leila EBRAHIMI, Maryam KHEIRANDISH, Mahnoosh FOROUGHI

The effect of methylprednisolone treatment on fibrinolysis, the coagulation system, and blood loss in cardiac surgery

Background/aim: The purpose of this study was to examine steroid pretreatment in order to decrease postoperative coagulopathy disorders and bleeding. Materials and methods: In this randomized double-blinded study, the efficacy of low versus high doses of methylprednisolone on the coagulation system and postoperative bleeding was compared in patients who were undergoing cardiac surgery with cardiopulmonary bypass (CPB). The platelet response to agonists, D-dimer concentration, tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) antigens, and platelet receptors CD42b, CD62P, and CD41a were evaluated. Results: The platelet response to agonists was reduced. The mean concentrations of D-dimer and tPA antigen increased although PAI1 concentration did not show any significant changes following heparin neutralization. Postoperative expression of CD42b showed no changes in comparison with preoperation values in both groups. There was a significant increase in the expression of CD62P with a methylprednisolone dose of 15 mg/kg, while there was just a slight increase with a dose of 5 mg/kg. CD41a, as a fibrinogen receptor, was increased significantly after CPB in both groups. Significant data were shown in decreasing blood loss with a high dose of methylprednisolone. Conclusion: Methylprednisolone at a dose of 15 mg/kg reduced bleeding, probably by increasing CD62P after heparin neutralization, which can activate platelet activation in favor of better hemostasis.

PDF

___

1. Kojima T, Gando S, Morimoto Y. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery. Thromb Res 2001; 104: 301-307.
2. Day JRS, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 2005; 3: 129-140.
3. Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 2008; 48: 2S-30S.
4. Robinson KL, Marasco SF. Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Heart Lung Circ 2001; 10: 142-153.
5. Boyle EM, Verrier ED, Spiess BD. Endothelial cell injury in cardiovascular surgery: the procoagulant response. Ann Thorac Surg 1996; 62: 1549-1557.
6. Mahdi AM, Webster NR. Perioperative systemic haemostatic agents. Brit J Anaesth 2004; 93: 842-858.
7. Ray MJ, Marsh NA, Just SJ, Perrin EJ, OBrien MF, Hawson GA. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. Ann Thorac Surg 1997; 63: 57-63.
8. Santamaria A, Mateo J, Muñíz-Díaz E, Oliver A, Murillo J, Litvan H, Souto JC, Fontcuberta J. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. Haematologica 2000; 85: 381-385.
9. Pelletier MP, Solymoss S, Lee A. Negative reexploration for cardiac postoperative bleeding: can it be therapeutic? Ann Thorac Surg 1998; 65: 999-1002.
10. Pagano D, Howell NJ, Freemantle N, Cunningham D, Bonser RS, Graham TR, Mascaro J, Rooney SJ, Wilson IC, Cramb R et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 2008; 135: 495-502.
11. Valen G, Eriksson E, Risberg B, Vaage J. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 1994; 8: 324-330.
12. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoprotein. Studies on resting and activated platelet and platelet membrane microparticles in normal subjects and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-348.
13. van Oeveren W, Kazatchkine MD, Descamps-Latscha B, Maillet F, Fischer E, Carpentier A, Wildevuur CR. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985; 89: 888-899.
14. Tassani P. Corticosteroids during operations using cardiopulmonary bypass. J Clin Anesth 2000; 12: 242-247.
15. Allen ML, Pathan N. Steroids in cardiac surgery: right time, right dose, and right patient group. Crit Care Med 2009; 37: 5: 1815.
16. Whitlock RP, Rubens FD, Teoh KH. Pro: Steroids should be used for cardiopulmonary bypass. J Cardiothor Vasc An 2005; 19: 250-254.
17. Chaney MA. Corticosteroids and cardiopulmonary bypass. A review of clinical investigations. Chest 2002; 121: 921-931.
18. Bourbon A, Vionnet M, Leprince P. The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response. Eur J Cardiothorac Surg 2004; 26: 932-938.
19. Sobieski MA 2nd, Graham JD, Pappas PS, Tatooles AJ, Slaughter MS. Reducing the effect of the systemic inflammatory response to cardiopulmonary bypass: can single dose steroids blunt systemic inflammatory response syndrome? ASAIO J 2008; 54: 203-206.
20. Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K, Teoh KH. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J 2008; 29: 2592-2600.
21. Varghese SJ, Unni MK, Mukundan N, Rai R. Platelet functions in cardiopulmonary bypass surgery. Med J Armed Forces India 2005; 61: 316-321.
22. Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Re-exploration for bleeding after coronary artery bypass surgery: risk factors, outcomes and the effect of time delay. Ann Thorac Surg 2004; 78: 527-534.
23. Nuttall GA, Fass DN, Oyen LJ, Oliver WC Jr, Ereth MH. A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery. Anesth Analg 2002; 94: 283-289.
24. Woodman RC, Harke LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680-1697.
25. Rinder CS, Mathew JP, Rinder HM, Bonan J, Ault KA, Smith BR. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 1991; 75: 563-570.
26. Chandler WL, Fitch JC, Wall MH, Verrier ED, Cochran RP, Soltow LO, Spiess D. Individual variation in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995; 74: 1293-1297.
27. Paparella D, Brister SJ, Buchanan MR. Coagulation disorder of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-1881.
28. Duggan E, ODwyer MJ, Caraher E, Diviney D, McGovern E, Kelleher D, McManus R, Ryan T. Coagulopathy after cardiac surgery may be influenced by a functional plasminogen activator inhibitor polymorphism. Anesth Analg 2007; 104: 1343-1347.
29. Oliver W, Nutall GA. Platelet function and cardiopulmonary bypass. In: Pifarre R, editor. Blood Conservation with Aprotinin. Philadelphia, PA, USA: Hanley & Belfus; 1995. pp. 83-102.
30. Bertolino G, Locatelli A, Noris P, Maurelli M, Ceriana P, Mazzini G, Spedini P, Belletti S, Balduini CL. Platelet composition and function in patients undergoing cardiopulmonary bypass for heart surgery. Haematologica 1996; 81: 116-120.
31. Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA, MacGregor H, Doursounian M, Zolkewitz MA. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 1008-1014.
32. Kanemitsu S, Nishikawa M, Onoda K, Shimono T, Shimpo H, Yazaki A, Tanaka K, Shiku H, Yada I. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonists and argatroban during in vitro extracorporeal circulation. J Thorac Cardiovasc Surg 2003; 126: 428-435.
33. Weerasinghe A, Taylork M. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 2145-2152.